Literature DB >> 26475633

Development and validation of a histological index for UC.

Mahmoud H Mosli1,2,3, Brian G Feagan1,2,4, Guangyong Zou1,4, William J Sandborn1,5, Geert D'Haens1,6, Reena Khanna1,2, Lisa M Shackelton1, Christopher W Walker1, Sigrid Nelson1, Margaret K Vandervoort1, Valerie Frisbie1, Mark A Samaan1, Vipul Jairath1,7,8, David K Driman9, Karel Geboes10, Mark A Valasek11, Rish K Pai12, Gregory Y Lauwers13,14, Robert Riddell15, Larry W Stitt1,4, Barrett G Levesque1,5.   

Abstract

OBJECTIVE: Although the Geboes score (GS) and modified Riley score (MRS) are commonly used to evaluate histological disease activity in UC, their operating properties are unknown. Accordingly, we developed an alternative instrument.
DESIGN: Four pathologists scored 48 UC colon biopsies using the GS, MRS and a visual analogue scale global rating. Intra-rater and inter-rater reliability for each index and individual index items were measured using intraclass correlation coefficients (ICCs). Items with high reliability were used to develop the Robarts histopathology index (RHI). The responsiveness/validity of the RHI and multiple histological, endoscopic and clinical outcome measures were evaluated by analyses of change scores, standardised effect size (SES) and Guyatt's responsiveness statistic (GRS) using data from a clinical trial of an effective therapy.
RESULTS: Inter-rater ICCs (95% CIs) for the total GS and MRS scores were 0.79 (0.63 to 0.87) and 0.80 (0.69 to 0.87). The correlation estimates between change scores in RHI and change score in GS and MRS were 0.75 (0.67 to 0.82) and 0.84 (0.79 to 0.88), respectively. The SES and GRS estimates for GS, MRS and RHI were: 1.87 (1.54 to 2.20) and 1.23 (0.97 to 1.50), 1.29 (1.02 to 1.56) and 0.88 (0.65 to 1.12), and 1.05 (0.79 to 1.30) and 0.88 (0.64 to 1.12), respectively.
CONCLUSIONS: The RHI is a new histopathological index with favourable operating properties. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  HISTOPATHOLOGY; ULCERATIVE COLITIS

Mesh:

Year:  2015        PMID: 26475633     DOI: 10.1136/gutjnl-2015-310393

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  61 in total

1.  Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.

Authors:  Vincent H Tam; Daniel N Cohen; Kimberly R Ledesma; Bobby Guillory; Katrina Chan; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

Review 3.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

4.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

5.  Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.

Authors:  Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2020-09-27       Impact factor: 8.171

Review 6.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

7.  18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.

Authors:  Yan Li; Benedikt Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Anna Katharina Koch; Ole Martin; Ken Herrmann; Hendrik Juette; Andrea Tannapfel; Jost Langhorst
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-24       Impact factor: 9.236

8.  Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.

Authors:  Michael J Rosen; Rebekah Karns; Jefferson E Vallance; Ramona Bezold; Amanda Waddell; Margaret H Collins; Yael Haberman; Phillip Minar; Robert N Baldassano; Jeffrey S Hyams; Susan S Baker; Richard Kellermayer; Joshua D Noe; Anne M Griffiths; Joel R Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Michael D Kappelman; James Markowitz; Dedrick E Moulton; Neal S Leleiko; Thomas D Walters; Subra Kugathasan; Keith T Wilson; Simon P Hogan; Lee A Denson
Journal:  Gastroenterology       Date:  2017-01-26       Impact factor: 22.682

Review 9.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

Review 10.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

Authors:  Mahmoud H Mosli; Claire E Parker; Sigrid A Nelson; Kenneth A Baker; John K MacDonald; G Y Zou; Brian G Feagan; Reena Khanna; Barrett G Levesque; Vipul Jairath
Journal:  Cochrane Database Syst Rev       Date:  2017-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.